Synonyms: (S)-naproxen | Aleve® | Naprosy®
naproxen is an approved drug (FDA (1976))
Compound class:
Synthetic organic
Comment: Naproxen is one of the 2-arylpropionic acid ('profen') family of nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: naproxen |
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects |
Naproxen inhibits cyclooxygenase enzymes COX-1 and COX-2 leading to a reduction in inflammation. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02052908 | Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome | Phase 1 Interventional | National Cancer Institute (NCI) | Naproxen demonstrates chemopreventive activity in patients with Lynch syndrome (LS), potentially via a mechanism that modulates the immune activation that is observed in LS colorectal adenomas and tumours. | 2 |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com |